Results 261 to 270 of about 4,431,933 (293)

Porto-Sinusoidal Vascular Disorder-Spectrum Portal Venopathy as a Structural Substrate for Portal Hypertension in Anti-Centromere Antibody-Positive Primary Biliary Cholangitis. [PDF]

Pathol Int
Ando Y, Mabuchi S, Nakayama S, Honda A, Hokari R, Harada K, Murashima N.   +6 more
europepmc   +1 more source

Population Pharmacokinetics and Pharmacokinetics-Pharmacodynamics Analyses of Elafibranor to Support Dose Selection in Primary Biliary Cholangitis. [PDF]

CPT Pharmacometrics Syst Pharmacol
Ooi QX, Brendel K, van Beek S, Zdovc JA, Bardol M, Dehez M.   +5 more
europepmc   +1 more source

Steatotic Liver Disease at Primary Biliary Cholangitis Diagnosis: Association With Ursodeoxycholic Acid Response and Outcomes. [PDF]

Liver Int
Del Barrio M, Sala M, Gómez J, Horta D, Hernández-Guerra M, Salcedo M, Goñi S, Ríos-León R, Herreros ÁM, González-Santiago JM, Martínez J, Quintans NC, Ampuero J, Antón MD, Fernández-de la Varga M, Escudero D, El Hajra I, Cuenca Alarcón F, Lorente S, Andrade RJ, Riveiro-Barciela M, Castello I, Vergara M, Quiñones R, Arencibía Almeida A, Blanco Sampascual S, Leal C, García-Retortillo M, Pérez-Medrano I, Fernández-Bermejo M, Morillas RM, Gómez E, Tejedor-Tejada J, Roget M, Rodríguez-Tajes S, Alonso-Peña M, Álvarez-Cancelo A, Londoño MC, Díaz-González Á.   +38 more
europepmc   +1 more source

Osteoporosis in primary biliary cholangitis: from cholestasis to fracture prevention. [PDF]

Clin Exp Hepatol
Andrzejuk A, Rogalska M, Rogalski P, Flisiak R.   +3 more
europepmc   +1 more source

Abstracts of 14th International Symposium on Hodgkin Lymphoma

HemaSphere, Volume 10, Issue S2, October 2026.
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.

New England Journal of Medicine, 2023
BACKGROUND Primary biliary cholangitis is a rare, chronic cholestatic liver disease characterized by the destruction of interlobular bile ducts, leading to cholestasis and liver fibrosis.
Kris V. Kowdley, C. Bowlus, Cynthia Levy, U. Akarca, M. Álvares-da-Silva, P. Andreone, M. Arrese, C. Corpechot, S. Francque, M. Heneghan, Pietro Invernizzi, David Jones, F. Kruger, E. Lawitz, M. Mayo, M. Shiffman, M. Swain, J. M. Valera, V. Vargas, J. Vierling, A. Villamil, Carol Addy, J. Dietrich, J. Germain, Sarah Mazain, D. Rafailovic, Bachirou O Taddé, Benjamin Miller, J. Shu, C. Zein, J. Schattenberg   +30 more
semanticscholar   +1 more source

Primary biliary cholangitis and the narrowing gap towards optimal disease control.

The Lancet Gastroenterology and Hepatology
Although infrequent, primary biliary cholangitis is not indolent and remains a burdensome chronic autoimmune biliary disease. Progressive biliary injury and cholestasis results in complications of biliary cirrhosis, with reduced quality and quantity of ...
G. Cançado, A. Lleo, Cynthia Levy, M. Trauner, G. Hirschfield   +4 more
semanticscholar   +1 more source

A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis.

New England Journal of Medicine
BACKGROUND Effective treatments for patients with primary biliary cholangitis are limited. Seladelpar, a peroxisome proliferator-activated receptor delta agonist, has potential benefits.
G. Hirschfield, C. Bowlus, M. Mayo, A. Kremer, J. Vierling, Kris V. Kowdley, C. Levy, A. Villamil, Alma L. Ladrón de Guevara Cetina, E. Janczewska, E. Zigmond, Sook-Hyang Jeong, Y. Yilmaz, Y. Kallis, C. Corpechot, P. Buggisch, Pietro Invernizzi, M. L. Londoño Hurtado, S. Bergheanu, Ke Yang, Yun-Jung Choi, D. Crittenden, C. McWherter   +22 more
semanticscholar   +1 more source